Breast Cancer

Latest News

DNA | Image credit: NHS
Breast Cancer and the Use of Predictive Genomics

June 18th 2025

Data suggest trastuzumab deruxtecan and pertuzumab may represent a new first-line standard of care for metastatic, HER2-positive breast cancer. | Image credit: Axel Kock - stock.adobe.com
Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer

June 2nd 2025

AJMC
Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

April 4th 2025

Screen-detected breast cancer. | Image Credit: keetazalay - stock.adobe.com
Interval Breast Cancer Risk High Despite Screening, Highlights Need for Risk-Based Approach

March 27th 2025

Diverse women and breast cancer support | Image Credit: ©Atstock Productions-stock.adobe.com
Same-Day Breast Imaging Gaps Reveal Health Care Disparities

February 18th 2025

Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

Experts discuss the impact of CDK4/G inhibitor use, including medication cost, total care costs, toxicity profiles, and strategies to manage and optimize patient outcomes in high-risk early breast cancer.

Watch the latest AJMC Peer Exchange on Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

More News

Image of FDA approval
May 5th 2022

FDA Approves Enhertu for Use in Metastatic Breast Cancer

Maggie L. Shaw
This approval of trastuzumab deruxtecan (Enhertu) follows the March release of data from the DESTINY-Breast03 trial on the anti-HER2 monoclonal antibody, also a HER2-directed antibody-drug conjugate, which indicated superior outcomes vs trastuzumab emtansine.
Hatem Soliman, MD
May 3rd 2022

Dr Hatem Soliman Explains Short-, Long-term Treatment Priorities for Metastatic Disease

Hayden E. Klein
The intent of metastatic disease treatment is palliative, not curative, so we try to prolong life and provide quality of life as much as we can, said Hatem Soliman, MD, medical director of the Clinical Trials Office, Moffitt Cancer Center.
Joneigh Khaldun, CVS Health.
April 27th 2022

Contributor: Helping Women of Color Achieve a Healthier Future

Joanne Armstrong, MD, MPH Joneigh Khaldun, MD, MPH, FACEP
To achieve health equity, experts from CVS Health discuss why we must invest in programs that improve access to health care for historically marginalized communities, address social determinants, boost health education, increase representation in all levels of health care delivery, widen access to clinical trial research, and more.
Hatem Soliman, MD
April 25th 2022

Dr Hatem Soliman Addresses the Economic Burden of Metastatic Breast Cancer Treatment

Hayden E. Klein
The financial toxicity of newer metastatic breast cancer (MBC) treatments is a significant concern and requires stakeholders to work together to find the best value- and evidence-based treatments for patients, said Hatem Soliman, MD, medical director, Clinical Trials Office, Moffitt Cancer Center.
Debra Patt, MD, PhD, MBA, Texas Oncology
April 23rd 2022

Dr Debra Patt: The True Impact of the Pandemic on Cancer Screenings, Diagnoses Is Not Yet Known

Mary Caffrey Maggie L. Shaw
Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, addresses how the pandemic may have influenced cancer screening and diagnosis rates.
Image of breast cancer screening
April 20th 2022

Breast MRI Linked to Greater Downstream Service Use, Costs vs Mammography

Maggie L. Shaw
This investigation focused on use of additional services and incidence of new diagnoses among women who underwent a breast cancer screening MRI—having a low or average risk of the cancer—compared with a matched cohort who underwent mammography.
Screenshot of Debra Patt, MD, PhD, MBA, Texas Oncology
April 16th 2022

Dr Debra Patt Discusses Considering Strategies for Additional COVID-19 Boosters in Breast Cancer

Mary Caffrey Maggie L. Shaw
Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, addresses considerations for getting a second COVID-19 booster, or a fourth dose, among survivors of breast cancer or patients currently undergoing treatment as well as those who may be immunocompromised.
Image of breast surgery
April 13th 2022

Choice of Breast Cancer Surgical Treatment Likely Influences Long-term QOL

Maggie L. Shaw
This new study used data on women with stage 0 to II breast cancer to investigate their long-term quality of life (QOL) as it related to choice of surgery and the decision to undergo adjuvant radiation therapy.
Image of women with breast cancer
April 9th 2022

Mixed QOL Findings Following Treatment Highlight Need for BC Support Services

Maggie L. Shaw
This subanalysis of data from the ECOG-ACRIN E5103 trial evaluated longer-term quality of life (QOL) at the 18-month mark among patients with lymph node–positive or high-risk lymph node–negative breast cancer (BC) who have completed active treatment.
Debra Patt, MD, PhD, MBA, Texas Oncology
April 4th 2022

Dr Debra Patt: Do Not Delay Diagnostic Visits for Breast Cancer

Mary Caffrey Maggie L. Shaw
Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, explains recommendations for annual mammography screenings after COVID-19 vaccination and why guidelines differ for diagnostic visits.
CDK4/6 Inhibitors, SERDs, and More in NCCN Talk on Breast Cancer Updates
April 1st 2022

CDK4/6 Inhibitors, SERDs, and More in NCCN Talk on Breast Cancer Updates

NCCN guidelines are no longer “a group of monotherapy choices,” but selections that feature partners for endocrine therapy, highlighted William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Image of Artificial Intelligence Being Used
March 29th 2022

AI Shows Promise in Detecting Breast Cancer in Women

Maggie L. Shaw
In this new study from Norway, artificial intelligence (AI) was used with mammography screenings to predict risk of breast cancer in women vs double reading of mammographic screening by independent radiologists.
Image of a breast surgeon
March 23rd 2022

MBC Outcomes Superior With Trastuzumab Deruxtecan vs Trastuzumab Emtansine

Maggie L. Shaw
This interim data analysis from the phase 3 DESTINY-Breast03 trial evaluated progression-free survival, overall survival, objective response, and safety between patients with metastatic breast cancer (mBC) progression following previous treatment failure.
heart graphic
March 21st 2022

Breast Arterial Calcification May Increase Risk of ASCVD

Gianna Melillo
The presence of breast arterial calcification may serve as a biomarker for an increased risk of cardiovascular disease among postmenopausal women.
Considerations to Increase Rates of Breast Cancer Screening Across Populations
March 14th 2022

Considerations to Increase Rates of Breast Cancer Screening Across Populations

Debra Patt, MD, PhD, MBA, MPH Lucio Gordan, MD Kashyap Patel, MD Ted Okon, MBA Nicolas Ferreyros, BA Nathan Markward, PhD, MPH Milena Sullivan, MA Blair Burnett, BA Brook Getachew, BA Crystal Harris, MPH
Authors from the Community Oncology Alliance and Avalere Health present data that show breast cancer screening rates recovered more slowly among some racial/ethnic groups following on the onset of the COVID-19 pandemic.
Image of FDA
March 14th 2022

Olaparib Approval Expands Breast Cancer Treatment Options

Maggie L. Shaw
The FDA based its approval on OlympiA trial data, which show the PARP inhibitor has the ability to reduce risks of invasive breast cancer recurrence, second cancers, and death, and to improve overall survival.
Dr Gregory Vidal: Some Populations Continue to Face Barriers to Care Despite Virtual Options
March 13th 2022

Dr Gregory Vidal: Some Populations Continue to Face Barriers to Care Despite Virtual Options

Laura Joszt, MA
Minority, low-income, and elderly patients faced greater barriers to care even when it went virtual during the pandemic, according to Gregory Vidal, MD, PhD, medical oncologist specializing in breast cancer at West Cancer Center.
Image of a woman speaking to a doctor
March 10th 2022

A DCIS Diagnosis Introduces Physical, Emotional Uncertainty for Many Women

Maggie L. Shaw
This new study focused on the patient perspective following a diagnosis of ductal carcinoma in situ (DCIS), a noninvasive type of breast cancer also referred to as stage 0 or pre-cancer, as well as their concerns over follow-up
Dr Gregory Vidal Highlights RPM Technologies for His Patients With Breast Cancer
March 6th 2022

Dr Gregory Vidal Highlights RPM Technologies for His Patients With Breast Cancer

Laura Joszt, MA
During the COVID-19 pandemic, there has been a lot of experimentation with new technologies for remote patient monitoring (RPM) to improve adherence and survival, according to Gregory Vidal, MD, PhD, medical oncologist specializing in breast cancer at West Cancer Center.
Debra Patt, MD, PhD, MBA, Texas Oncology
March 2nd 2022

Dr Debra Patt Discusses Ongoing Pandemic-Related Delays in Cancer Screenings

Mary Caffrey Maggie L. Shaw
Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, addresses roadblocks to cancer screenings first thrown up by the COVID-19 pandemic in 2020 and that continue to reverberate today.
Image of a mammography review
February 28th 2022

Possibility of Breast Cancer Overdiagnosis Should Inform Mammography Decisions

Maggie L. Shaw
This new study of women who underwent mammographic screening for breast cancer at a Breast Cancer Surveillance Consortium facility between 2000 and 2018 investigated potential implications of overdiagnosis.
Dr Funmi Olopade
February 20th 2022

Dr Funmi Olopade Describes Advancements in BRCA Gene Testing

Hayden E. Klein
Funmi Olopade, MD, FACP, professor of medicine and human genetics and founding director of the Center for Clinical Cancer Genetics and Global Health at the University of Chicago Medical Center, explains advancements in BRCA testing and how genetic testing has become standard of care.
Image of mammography results
February 17th 2022

Family History of Breast Cancer, Breast Density May Be Linked

Maggie L. Shaw
This study investigated the relationships seen among premenopausal women with a family history of breast cancer and their breast tissue density as seen at their annual mammographic screening.
Kenneth Cohen, MD, FACP
February 15th 2022

Dr Kenneth Cohen: Low-Value Care Exists Across the Health Care System

Mary Caffrey Hayden E. Klein
Kenneth Cohen, MD, FACP, executive director of clinical research at UnitedHealth Group Research and Development and senior national medical director at OptumCare, discusses areas where low-value care is more prevalent and the shift to high-value care.
Image of a linear accelerator
February 9th 2022

PMRT Likely to Have Greater Benefit in Advanced Breast Cancer

Maggie L. Shaw
A new report from the Republic of Korea compared outcomes among women following neoadjuvant chemotherapy and mastectomy who did or did not receive radiotherapy.
Image of a doctor administering a vaccine
February 7th 2022

mRNA COVID-19 Vaccines Safe Among Patients With Cancer History

Maggie L. Shaw
A study from investigators at Fox Chase Cancer Center sought comparative outcomes data on adverse reactions from COVID-19 vaccination among patients with a history of cancer and those undergoing treatment and found equivalent safety outcomes.
Image of a woman with breast cancer
February 5th 2022

Breast Cancer Treatment May Increase Risk of Diabetes, Hypertension

Maggie L. Shaw
Although cardiovascular disease risk is well established in survivors of breast cancer, how cardiotoxicity from treatment influences development of cardiometabolic risk factors is not.
Image of a slide under a microscope
February 2nd 2022

Precision Treatment With TIL Shows Promise in Metastatic Breast Cancer

Maggie L. Shaw
Interim data from a National Cancer Institute Center for Cancer Research study show demonstrated immune reactions in patients with breast cancer following immunotherapy with their own tumor-infiltrating lymphocytes (TIL).
Image of a map of the United States
January 27th 2022

Persistent Care Variations Uncovered in New Breast Cancer Study

Maggie L. Shaw
This new analysis among patients with stage I to III breast cancer investigated outcomes in connection with 5 care delivery variables: stage I at diagnosis, chemotherapy receipt, radiation therapy receipt, endocrine therapy initiation, and endocrine therapy continuation.
Image of a breast cancer ribbon
January 21st 2022

Novel, Existing Biomarkers Advance Targeted Breast Cancer Care

Maggie L. Shaw
Given the heterogeneous nature of breast cancer, biomarkers evaluated throughout treatment help provide a clearer picture of the treatment paradigm.
<12345678910
...
13>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo